Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171262

Enrollment

120

Registered

2005-09-15

Start date

2004-08-31

Completion date

2007-06-30

Last updated

2017-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Keywords

Dyslipidemia, chronic renal disease, fluvastatin

Brief summary

To analyze efficacy of fluvastatin on patients with chronic renal disease by analyzing certain inflammatory markers. In addition, tolerability and safety will also be evaluated in a Spanish population.

Interventions

DRUGFluvastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patients \> 18 years Patients that give their inform consent

Exclusion criteria

* Pregnant women Diabetic patients Treated with statins for the year prior to study inclusion Patients with contraindications listed in fluvastatin prescribing information Other protocol-defined in and

Design outcomes

Primary

Measure	Time frame
Change from baseline in serum inflammatory markers after 52 weeks	—

Secondary

Measure	Time frame
Change from baseline in fibrosis parameters and endothelial function after 52 weeks	—
Adverse events and serious adverse events after 52 weeks	—
Change from baseline in laboratory tests of kidney function after 12 weeks	—

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026